Other

Societe Valbiofrance

Therapeutiques Substitutives

Jean-Pierre Caruelle

Denis S Barritault

Anne Meddahi

Jean Gautron

Jacqueline Jozefonvicz

Jose P Courty

Ahmed Aamiri

Pascal Desgranges

Michele Tardieu

Faouzi Slaoui

A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AXYwherein: A represents a monomer selected from the group consisting of a sugar or &#x2014;(O&#x2014;CH&#x2014;CH&#x2014;CO)&#x2014;, X represents a carboxyl group bonded to monomer A, Y represents a sulfate or sulfonate group bonded to monomer A a represents the number of monomers A such that the mass of the polymers of formula (I) is greater than approximately 5,000 da, x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.

Biocompatible polymers, process for their preparation and compositions containing them

A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AXYwherein: A represents a monomer selected from the group consisting of a sugar or &#x2014;(O&#x2014;CH&#x2014;CH&#x2014;CO)&#x2014;, X represents a carboxyl group bonded to monomer A and is contained within a group according to the following formula: &#x2014;R&#x2014;COO&#x2014;R', in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R&#x2032; represents a hydrogen atom or a cation, Y represents a sulfate or sulfonate group bonded to monomer A and is contained within a group according to one of the following formulas: &#x2014;R&#x2014;O&#x2014;SO&#x2014;R&#x2032;, &#x2014;R&#x2014;N&#x2014;SO&#x2014;R&#x2032;, &#x2014;R&#x2014;SO&#x2014;R&#x2032;, in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R&#x2032; represents a hydrogen atom or a cation, a represents the number of monomers A such that the mass of the polymers of formula (I) is greater than approximately 5,000 da, x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.

A biocompatible polymer constituted by a sequence of identical or different components of the general formula (I): AXY, in which A represents a monomer, X represents a carboxyl group fixed on a monomer A, Y represents a sulfate or sulfonate group fixed on a monomer A; a represents the number of monomers A, x represents the substitution rate of the set of monomers A by the groups X, y represents the substitution rate of the set of monomers A by the groups Y. The invention also pertains to the pharmaceutical or diagnostic compositions containing at least one polymer of general formula (I).

Process for treating fibroses with biocompatible polymer

A biocompatible polymer constituted by a sequence of identical or different components of the general formula (I): A X Y , in which A represents a monomer, X represents a carboxyl group fixed on a monomer A, Y represents a sulfate or sulfonate group fixed on a monomer A; a represents the number of monomers A, x represents the substitution rate of the set of monomers A by the groups X, y represents the substitution rate of the set of monomers A by the groups Y. The invention also pertains to the pharmaceutical or diagnostic compositions containing at least one polymer of general formula (I).

Use of at least one polymer or one biopolymer called HBGFPP, specifically protecting the growth factors of FGFs and beta TGFs families from tryptic degradation in the manufacture of a drug for the treatment of lesions of the nervous system.

Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate

Drug and pharmaceutical composition for the treatment of lesions of the

Drug and pharmaceutical composition for the treatment of muscles

Compositions useful for regenerating cells and tissues comprise at least one functionalized dextran which has been substituted with carboxymethyl, benzylamide, or benzylamide sulfonate. These dextrans can be used alone or in combination with acid or basic fibroblast growth factors to enhance tissue or cell regeneration. Additionally, these dextrans enhance the stability of acid or basic fibroblast growth factors.

Growing community of inventors

Saint Maur des Fosses, France

Jean-Pierre Caruelle